Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
Shionogi said on September 12 that it has been ordered by tax authorities to pay some 1.3 billion yen in back taxes over a deal associated with its joint venture with British HIV specialty firm ViiV Healthcare. The Osaka Regional…
To read the full story
Related Article
- Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
May 10, 2021
- High Court Backs Positive Ruling for Shionogi in Osaka Tax Suit
April 16, 2021
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Shionogi Cuts Half-Year Net Profit Projection on Back Taxes
October 21, 2014
BUSINESS
- Takeda CEO Says Orzeyful Could Redefine NT1 Standard of Care
July 31, 2026
- Pfizer Seeks Pediatric Expansion for Hympavzi in Japan
July 31, 2026
- Nippon Shinyaku Exercises Option for AB2 Bio’s Tadekinig Alfa in US
July 31, 2026
- Alfresa Takes Stake in Ember to Bolster Pharma Cold Chain in Japan
July 31, 2026
- Sanwa Kagaku Says Kumamoto Plant Remains Shut, Drug Supplies Stable
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…